share_log

Pono Capital Corp Combination Partner Benuvia Receives Approval From DEA To Manufacture Psychedelic Active Pharmaceutical Ingredients including Psilocybin, MDMA And DMT

Benzinga Real-time News ·  May 16, 2022 07:51
  • With this approval, Benuvia has begun focusing on four primary psychedelic ingredients: Psilocybin, N,N-Dimethyl-5-Methoxy-Tryptamine (5-MeO DMT), Dimethyltryptamine (DMT), and 3,4-Methylenedioxymethamphetamine, or MDMA
  • Benuvia will manufacture psychedelic APIs in its 83,000 square foot manufacturing facility that is permitted by the US DEA for Schedule I to III Controlled Substances, and is FDA registered and a cGMP facility
  • Benuvia is positioning itself to become a leading global supplier of psychedelic active pharmaceutical ingredients (APIs), complementing its established portfolio of cannabinoid APIs

ROUND ROCK, Texas, May 16, 2022 /PRNewswire/ -- Benuvia, Inc., a drug developer and manufacturer of APIs focused on cannabinoids, with...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment